乾癬：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 23
3.2 Symptoms 26
4 Epidemiology 27
4.1 Risk Factors and Comorbidities 27
4.1.1 Family history of psoriasis increases the risk of developing the disease by nearly 20 times 28
4.1.2 Obesity doubles the risk of psoriasis 28
4.1.3 Smoking, combined with other risk factors, increases the risk for psoriasis up to nine times 29
4.1.4 Psoriatic arthritis is present in up to 40.0% of all psoriasis patients 30
4.1.5 Nearly half of all psoriasis patients report elevated stress levels, depression, and thoughts of suicide 31
4.2 Global and Historical Trends 32
4.2.1 US 32
4.2.2 5EU 33
4.2.3 Japan 34
4.2.4 China 34
4.2.5 India 35
4.3 Forecast Methodology 36
4.3.1 Sources Used 36
4.3.2 Forecast Assumptions and Methods 40
4.3.3 Sources Not Used 44
4.4 Epidemiology Forecast (2012-2022) 45
4.4.1 Prevalent Cases of Psoriasis 45
4.4.2 Age-Specific Prevalent Cases of Psoriasis 47
4.4.3 Sex-Specific Prevalent Cases of Psoriasis 50
4.4.4 Age-Standardized Prevalence of Psoriasis 52
4.5 Discussion 53
4.5.1 Conclusions on Epidemiology Trends 53
4.5.2 Limitations of the Analysis 54
4.5.3 Strengths of the Analysis 55
5 Disease Management 56
5.1 Treatment Overview 57
5.2 US 60
5.2.1 Diagnosis 60
5.2.2 Clinical Practice 61
5.3 France 63
5.3.1 Diagnosis 63
5.3.2 Clinical Practice 63
5.4 Germany 65
5.4.1 Diagnosis 65
5.4.2 Clinical Practice 66
5.5 Italy 67
5.5.1 Diagnosis 67
5.5.2 Clinical Practice 67
5.6 Spain 69
5.6.1 Diagnosis 69
5.6.2 Clinical Practice 69
5.7 UK 71
5.7.1 Diagnosis 71
5.7.2 Clinical Practice 71
5.8 Japan 73
5.8.1 Diagnosis 73
5.8.2 Clinical Practice 73
5.9 China 75
5.9.1 Diagnosis 75
5.9.2 Clinical Practice 75
5.10 India 77
5.10.1 Diagnosis 77
5.10.2 Clinical Practice 77
6 Competitive Assessment 79
6.1 Overview 79
6.2 Strategic Competitor Assessment 80
6.3 Product Profiles – Major Brands 81
6.3.1 Enbrel (etanercept) 81
6.3.2 Humira (adalimumab) 88
6.3.3 Remicade (infliximab) 93
6.3.4 Stelara (ustekinumab) 99
6.3.5 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 104
6.3.6 Methotrexate Sodium (numerous generic names) 109
6.3.7 Minor Therapeutic Drug Classes Used in Psoriasis 113
6.3.8 Non-Pharmacological Therapy 114
7 Opportunity and Unmet Need 116
7.1 Overview 116
7.2 Unmet Needs 117
7.2.1 Improved Drug Safety and Efficacy Profiles 117
7.2.2 Biomarkers for Predicting Remission 117
7.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 118
7.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 118
7.2.5 An Effective Biologic/Systemic Topical Therapy 119
7.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 119
7.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 119
7.3 Opportunities 120
7.4 Unmet Needs Gap Analysis 120
7.4.1 Predictive Tools for Diagnosis and Treatment 121
7.4.2 Target Specificity 121
7.4.3 Topical Biologic/Systemic Therapeutic Options 121
7.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 122
8 Pipeline Assessment 123
8.1 Overview 123
8.2 Clinical Trial Mapping 124
8.2.1 Clinical Trials by Country 124
8.3 Clinical Trials by Phase and Trial Status 125
8.4 Promising Drugs in Clinical Development 126
8.4.1 Brodalumab (AMG 827) 128
8.4.2 Secukinumab (AIN457) 134
8.4.3 Ixekizumab (LY2439821) 139
8.4.4 Tildrakizumab (MK-3222/SCH-900222) 145
8.4.5 Xeljanz (tofacitinib) 150
8.4.6 Apremilast (CC-10004) 156
8.4.7 Alzumab (itolizumab) 162
8.4.8 Phase II Pipeline Products 166
8.4.9 Phase I Pipeline Products 167
8.4.10 Biosimilars Pipeline Products 168
9 Current and Future Players 171
9.1 Overview 171
9.2 Trends in Corporate Strategy 174
9.3 Company Profiles 176
9.3.1 Amgen 176
9.3.2 AbbVie (Abbott) 178
9.3.3 Johnson & Johnson 180
9.3.4 Novartis 182
9.3.5 Pfizer 184
9.3.6 Eli Lilly 186
9.3.7 Merck 188
9.3.8 LEO Pharma 190
9.3.9 Celgene 192
10 Market Outlook 194
10.1 Global Markets 194
10.1.1 Forecast 194
10.1.2 Drivers and Barriers – Global Issues 198
10.2 United States 202
10.2.1 Forecast 202
10.2.2 Key Events 205
10.2.3 Drivers and Barriers 205
10.3 France 208
10.3.1 Forecast 208
10.3.2 Key Events 211
10.3.3 Drivers and Barriers 211
10.4 Germany 213
10.4.1 Forecast 213
10.4.2 Key Events 216
10.4.3 Drivers and Barriers 216
10.5 Italy 218
10.5.1 Forecast 218
10.5.2 Key Events 221
10.5.3 Drivers and Barriers 222
10.6 Spain 223
10.6.1 Forecast 223
10.6.2 Key Events 226
10.6.3 Drivers and Barriers 226
10.7 United Kingdom 228
10.7.1 Forecast 228
10.7.2 Key Events 231
10.7.3 Drivers and Barriers 231
10.8 Japan 234
10.8.1 Forecast 234
10.8.2 Key Events 237
10.8.3 Drivers and Barriers 237
10.9 China 240
10.9.1 Forecast 240
10.9.2 Key Events 242
10.9.3 Drivers and Barriers 242
10.10 India 244
10.10.1 Forecast 244
10.10.2 Key Events 246
10.10.3 Drivers and Barriers 246
11 Appendix 248
11.1 Bibliography 248
11.2 Abbreviations 260
11.3 Methodology 263
11.4 Forecasting Methodology 263
11.4.1 Diagnosed Psoriasis Patients 263
11.4.2 Percent Drug-Treated Patients 264
11.4.3 Drugs Included in Each Therapeutic Class 264
11.4.4 Launch and Patent Expiry Dates 265
11.4.5 General Pricing Assumptions 266
11.4.6 Individual Drug Assumptions 267
11.4.7 Generic Erosion 270
11.4.8 Pricing of Pipeline agents 271
11.5 Physicians and Specialists Included in this Study 272
11.6 Primary Research – Prescriber Survey 273
11.7 About the Authors 274
11.7.1 Analysts 274
11.7.2 Epidemiologist 275
11.7.3 Reviewers 276
11.7.4 Global Director of Epidemiology and Clinical Trials Analysis 277
11.7.5 Global Head of Healthcare 277
11.8 About GlobalData 278
11.9 Contact Us 278
11.10 Disclaimer 278